Last reviewed · How we verify

Bupivacaine low dose

Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias · FDA-approved active Small molecule

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local anesthesia for surgical and diagnostic procedures, Regional anesthesia (nerve blocks, epidural, spinal anesthesia).

At a glance

Generic nameBupivacaine low dose
SponsorFundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, inhibiting sodium influx and preventing depolarization. This action halts the generation and conduction of nerve impulses in the area where it is administered. The low-dose formulation is designed to minimize systemic toxicity while maintaining local anesthetic efficacy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: